Product Pathways - Apoptosis
PKC412 #9493
- Molecular Formula:
- C35H30N4O4
- Molecular Weight:
- 570.65 g/mol
- Purity:
- >99%
Directions for Use
PKC412 is supplied as a lyophilized powder. For a 1 mM stock, reconstitute 1 mg in 1.75 mL DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used at 0.1-10 μM for 18-48 hours. Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water with maximum solubility estimated to be about 10-20 μM.
Western Blotting
Western blot analysis of extracts from Jurkat cells, untreated or treated with Calyculin A #9902 (50 nM, 20 min) with or without pre-treatment with PKC412 (24 hr) for the indicated concentrations, using Phospho-(Ser) PKC Substrate Antibody #2261 (upper) and β-Actin (13E5) Rabbit mAb #4970 (lower).
Western Blotting
Western blot analysis of extracts from SEM cells, untreated (-) or treated with PKC412 (1 μM, 24 hr; +), using Phospho-FLT3 (Tyr589/591) (30D4) Rabbit mAb #3464 (upper) and FLT3 (8F2) Rabbit mAb #3462 (lower).
Structure
Chemical structure of PKC412.
Background
The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine kinase activity (IC50 = 3.0 µM) (1). PKC412 has also demonstrated stong inhibitory effects on FLT3, which causes G1 cell cycle arrest and apoptosis (2).
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
